Duke Capital Partners — 2021 Investments
3 investments dated 2021 · listed companies and verified rows first · show all
Sparta Biomedical develops chemically engineered cartilage implants built on its Hyalos hydrogel platform, including Karthyx, an MTP hemiarthroplasty device that combines the cartilage-mimicking hydrogel with a titanium fixation technology.
BiotechHealthtechMedical DevicesMadison, US
Dushyanth Surakanti(Executive Officer, Director)inKen Gall(Director)Dimitrios Angelis(Executive Officer, Director)Sean Fontenot(Director)
Superb AI provides an industrial AI stack for vision and analytics applications across mobility, security, defense, logistics, and manufacturing.
AI & Machine LearningDeep TechDeveloper ToolsEnterprise SoftwareSaaSSan Francisco, US
Hyun Kim(Founder)inMoonsu Cha(Founder)inJonghyuk Lee(Founder)inJungkwon Lee(Founder)inHyundong Lee(Founder)Jung Kwon Lee(Founder)
Co-investorsAtinum Investment Co. Ltd.KT investment Inc.Premier PartnersSamsung NextY CombinatorPegasus Tech Ventures
Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets.
AI & Machine LearningBiotechDeep TechDurham, US
Mark A. Hallen(Executive Officer, Director)Marcel Frenkel(Executive Officer, Director)Damien Petty(Director)Jia Wei Xu(Director)
Co-investorsCape Fear BioCapitalDFJ DragonFundHatteras Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.